866-997-4948(US-Canada Toll Free)

Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Published By :

GlobalData

Published Date : Dec 2016

Category :

Cancer

No. of Pages : 467 Pages

Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Summary

GlobalData's Medical Devices sector report, Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" provides an overview of Lung Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Lung Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Lung Cancer Diagnostic Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Lung Cancer Diagnostic Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Lung Cancer Diagnostic Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the products current stage of development, territory and estimated launch date
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 12
1.2 List of Figures 23
2 Introduction 24
2.1 Lung Cancer Diagnostic Tests Overview 24
3 Products under Development 25
3.1 Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 25
3.2 Lung Cancer Diagnostic Tests - Pipeline Products by Territory 26
3.3 Lung Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 27
3.4 Lung Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 28
3.5 Lung Cancer Diagnostic Tests - Ongoing Clinical Trials 29
4 Lung Cancer Diagnostic Tests - Pipeline Products under Development by Companies 30
4.1 Lung Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 30
4.2 Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 35
5 Lung Cancer Diagnostic Tests Companies and Product Overview 40
5.1 A&G Pharmaceutical Inc Company Overview 40
5.2 Abbott Diagnostics Company Overview 42
5.3 Abcodia Ltd Company Overview 49
5.4 Aberystwyth University Company Overview 51
5.5 Acobiom Company Overview 52
5.6 Advanced Marker Discovery SL Company Overview 53
5.7 Advpharma Inc Company Overview 55
5.8 AIT Austrian Institute of Technology GmbH Company Overview 57
5.9 Almac Diagnostics Ltd Company Overview 58
5.10 Armune BioScience, Inc. Company Overview 60
5.11 Aurelium BioPharma Inc. Company Overview 61
5.12 Avant Diagnostics, Inc. Company Overview 62
5.13 BioAffinity Technologies, Inc. Company Overview 63
5.14 Biocept Inc Company Overview 64
5.15 BioChain Institute Inc Company Overview 66
5.16 Biodesix Inc Company Overview 68
5.17 BioMark Diagnostics Inc. Company Overview 69
5.18 BioMarker Strategies LLC Company Overview 70
5.19 BioNTech AG Company Overview 72
5.20 BioSystems International Company Overview 73
5.21 BioTime Inc Company Overview 74
5.22 Cangen Biotechnologies Inc Company Overview 76
5.23 Cellanyx Diagnostics, Inc. Company Overview 77
5.24 CellMax Life Company Overview 78
5.25 CeMines, Inc. Company Overview 79
5.26 Cepheid Company Overview 80
5.27 Ceres Nanosciences Inc Company Overview 82
5.28 Cernostics Inc. Company Overview 83
5.29 ChemImage Corporation Company Overview 84
5.30 Children's Hospital Boston Company Overview 85
5.31 Clarient Inc Company Overview 86
5.32 Courtagen Life Sciences Inc Company Overview 88
5.33 DiagnoCure Inc. (Inactive) Company Overview 89
5.34 EDP Biotech Corporation Company Overview 91
5.35 Emory University Company Overview 92
5.36 Epigenomics AG Company Overview 93
5.37 Eventus Diagnostics Inc (Inactive) Company Overview 95
5.38 Exact Sciences Corp Company Overview 96
5.39 Exiqon A/S Company Overview 98
5.40 Exosomics Siena SpA Company Overview 99
5.41 Fahy Gurteen UK Ltd Company Overview 100
5.42 Fina Biotech Company Overview 101
5.43 Fluxion Biosciences, Inc. Company Overview 102
5.44 Forschungszentrum Borstel Company Overview 103
5.45 French National Institute of Health and Medical Research Company Overview 104
5.46 Gene Express, Inc. (Inactive) Company Overview 105
5.47 GeneCentric Diagnostics, Inc. Company Overview 107
5.48 GenomicTree Inc Company Overview 108
5.49 Global Discovery Biosciences Corporation Company Overview 110
5.50 GlycoZym Company Overview 111
5.51 HalioDx SAS Company Overview 112
5.52 HTG Molecular Diagnostics Inc Company Overview 113
5.53 ImmunoCellular Therapeutics Ltd Company Overview 115
5.54 Inivata Ltd Company Overview 117
5.55 Insight Genetics Inc Company Overview 119
5.56 InterGenetics Inc Company Overview 122
5.57 IV Diagnostics, Inc. Company Overview 123
5.58 Janssen Biotech Inc Company Overview 124
5.59 Laboratorios SALVAT SA Company Overview 125
5.60 Louisville Bioscience, Inc. Company Overview 126
5.61 Mayo Clinic US Company Overview 127
5.62 MDNA Life Sciences Inc Company Overview 128
5.63 MDxHealth SA Company Overview 129
5.64 MEDITE Cancer Diagnostics Inc Company Overview 131
5.65 Memory Dx LLC Company Overview 133
5.66 Merrimack Pharmaceuticals Inc Company Overview 134
5.67 Metabolon Inc Company Overview 136
5.68 Metanomics Health GmbH Company Overview 137
5.69 MetaStat Inc Company Overview 139
5.70 Milagen, Inc. Company Overview 141
5.71 Nanocytomics LLC Company Overview 142
5.72 Nanopore Diagnostics, LLC Company Overview 144
5.73 NEOMICS Co Ltd Company Overview 145
5.74 Novel Bio-spectrum Technologies Inc Company Overview 146
5.75 Nuvera Biosciences Inc Company Overview 147
5.76 OncoCyte Corp Company Overview 148
5.77 Oncolome Diagnostics Inc (Inactive) Company Overview 152
5.78 Onconome, Inc. (Inactive) Company Overview 153
5.79 OncoStem Diagnostics Pvt. Ltd Company Overview 154
5.80 On-Q-ity, Inc. (Inactive) Company Overview 155
5.81 OPKO Health Inc Company Overview 156
5.82 Orion Genomics LLC Company Overview 158
5.83 OTraces Inc. Company Overview 159
5.84 Oxford Gene Technology Ltd Company Overview 160
5.85 PeriRx LLC Company Overview 161
5.86 PleX Diagnostics Company Overview 163
5.87 Precision Biologics Inc Company Overview 164
5.88 PreMD Inc Company Overview 165
5.89 Proplex Technologies Llc Company Overview 166
5.90 Proteome Sciences Plc Company Overview 167
5.91 Proteomika Company Overview 169
5.92 Provista Diagnostics Inc Company Overview 170
5.93 Quest Diagnostics Inc Company Overview 171
5.94 Roche Diagnostics International Ltd Company Overview 174
5.95 Rosetta Genomics Ltd Company Overview 180
5.96 Roswell Park Cancer Institute Company Overview 182
5.97 Savicell Diagnostic Ltd. Company Overview 183
5.98 Siemens Healthcare GmbH Company Overview 185
5.99 Sienna Cancer Diagnostics Ltd Company Overview 187
5.100 Simon Fraser University Company Overview 188
5.101 Sividon Diagnostics GmbH Company Overview 189
5.102 SomaLogic Inc Company Overview 190
5.103 Southern Illinois University Carbondale Company Overview 192
5.104 Syndax Pharmaceuticals Inc Company Overview 193
5.105 The Wistar Institute Company Overview 195
5.106 Todos Medical Company Overview 196
5.107 Transgene SA Company Overview 197
5.108 Trinity College Dublin Company Overview 199
5.109 Universal Diagnostics, S. L. Company Overview 200
5.110 University of California San Francisco Company Overview 201
5.111 University of Chicago Company Overview 202
5.112 University of Colorado Company Overview 204
5.113 University of South Florida Company Overview 205
5.114 University of Strathclyde Company Overview 206
5.115 US Biomarkers Inc Company Overview 207
5.116 Vanderbilt University Company Overview 208
5.117 Ventana Medical Systems Inc Company Overview 209
5.118 Vigilant Biosciences, Inc. Company Overview 210
5.119 Viomics Inc. Company Overview 211
5.120 VisionGate, Inc. Company Overview 212
5.121 Vitatex Inc. Company Overview 213
5.122 VolitionRX Ltd Company Overview 214
5.123 Weizmann Institute of Science Company Overview 217
5.124 XEPTAGEN SpA Company Overview 218
5.125 Zetiq Technologies Ltd Company Overview 220
6 Lung Cancer Diagnostic Tests - Recent Developments 221
6.1 Nov 23, 2016: Rosetta Genomics to Raise USD3.7 Million in Private Placement 221
6.2 Nov 23, 2016: Rosetta Genomics to Raise USD1.3 Million in Private Placement of Debentures 221
6.3 Nov 22, 2016: OGT announces commercial and financial highlights for FY 2016 221
6.4 Nov 21, 2016: Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply to Retire 222
6.5 Nov 21, 2016: Veracyte appoints new CFO 223
6.6 Nov 15, 2016: Aurora Diagnostics to Offer Assay to Aid in the Selection of TECENTRIQ Therapy in Lung Cancer 223
6.7 Nov 15, 2016: bioAffinity Technologies Announces Award of Hong Kong Patent 224
6.8 Nov 15, 2016: Agilent Technologies Reports Fourth-Quarter 2016 Results 224
6.9 Nov 14, 2016: HTG Molecular Diagnostics Reports Third Quarter 2016 Results 225
6.10 Nov 10, 2016: Siemens Healthcare Plans IPO of Shares 226
6.11 Nov 10, 2016: ImmunoCellular Therapeutics Announces Third Quarter 2016 Financial Results and Provides Research and Development Update 226
6.12 Nov 10, 2016: Syndax Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update 228
6.13 Nov 10, 2016: AstraZeneca: Year-To-Date and Q3 2016 Results 229
6.14 Nov 10, 2016: VolitionRx Announces Third Quarter 2016 Financial Results and Business Update 242
6.15 Nov 09, 2016: Epigenomics Announces 2016 Third Quarter and Nine Months Financial Results and Reports on Operational Highlights 243
6.16 Nov 09, 2016: Biocept Reports 2016 Third Quarter Financial Results 244
6.17 Nov 09, 2016: Change To Astrazeneca Board Of Directors 246
6.18 Nov 08, 2016: Exact Sciences Appoints Jeff Elliott Chief Financial Officer 246
6.19 Nov 07, 2016: FDA approves Roches VENTANA ALK (D5F3) CDx Assay for use on the VENTANA BenchMark ULTRA system 247
6.20 Nov 07, 2016: FDA approves Roches VENTANA ALK (D5F3) CDx Assay for use on the VENTANA BenchMark ULTRA system 247
6.21 Nov 07, 2016: HalioDx launches Immunoseek CR (CD8/PD-L1), a new assay toward precision immunotherapy 248
6.22 Nov 07, 2016: OPKO Health Reports Third Quarter Financial and Operating Results 248
6.23 Nov 03, 2016: BioTime Reports Third Quarter Results and Recent Clinical Progress 250
6.24 Nov 03, 2016: Insmed Reports Third Quarter 2016 Financial Results and Provides Business Update 252
6.25 Nov 03, 2016: Veracyte Announces Third Quarter 2016 Financial Results 253
6.26 Nov 02, 2016: MDxHealth Raises USD22.4 Million in Private Placement of Shares 254
6.27 Nov 02, 2016: MDxHealth Provides Third Quarter 2016 Business Update 254
6.28 Nov 02, 2016: QIAGEN Reports Results for Third Quarter and First Nine Months of 2016 256
6.29 Nov 01, 2016: Veracyte Prices Public Offering of Shares for USD30 Million 258
6.30 Nov 01, 2016: Pfizer Reports Third-Quarter 2016 Results 259
6.31 Nov 01, 2016: Illumina Reports Full Financial Results for Third Quarter of Fiscal Year 2016 263
6.32 Oct 31, 2016: Biodesix VeriStrat Test Now Covered By Humana, Medical Mutual of Ohio, PreferredOne 265
6.33 Oct 31, 2016: Proteome Sciences to Raise USD4 Million in Private Placement of Shares 265
6.34 Oct 27, 2016: Roche announces FDA approval for VENTANA PD-L1 (SP142) Assay to support immunotherapy treatment decisions in lung cancer 265
6.35 Oct 27, 2016: Biocept Appoints David Moskowitz Vice President, Strategy & Corporate Communications 266
6.36 Oct 26, 2016: Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 267
6.37 Oct 26, 2016: Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 267
6.38 Oct 26, 2016: Laboratory Corporation of America Holdings Announces 2016 Third Quarter Results and Updates 2016 Guidance 268
6.39 Oct 26, 2016: GlaxoSmithKline: Results Announcement for the third quarter 2016 270
6.40 Oct 25, 2016: VisionGate Raises Funds through Venture Financingc 276
6.41 Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters 276
6.42 Oct 25, 2016: Merck Announces Third-Quarter 2016 Financial Results 282
6.43 Oct 24, 2016: Agilent Technologies Receives Expanded FDA Approval for Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Non-Small Cell Lung Cancer 285
6.44 Oct 20, 2016: Transgene to Raise USD52.61 Million in Rights Offering of Shares 286
6.45 Oct 20, 2016: Transgene Reports Third Quarter 2016 Financial Results 287
6.46 Oct 20, 2016: Quest Diagnostics Reports Third Quarter 2016 Financial Results 288
6.47 Oct 20, 2016: Rosetta Genomics Appoints Mark R. Willig as Chief Commercial Officer 289
6.48 Oct 17, 2016: OncoCyte and The Wistar Institute Present Lung Cancer Diagnostic Data at the CHEST 2016 Annual Meeting 290
6.49 Oct 17, 2016: Veracyte Releases Preliminary Third Quarter 2016 Financial Results 291
6.50 Oct 14, 2016: Biocept Raises USD10 Million in Public Offering of Shares and Warrants 291
6.51 Oct 13, 2016: Provista Diagnostics Raises USD2.6 Million in Venture Financing 292
6.52 Oct 13, 2016: Enzo Biochem Reports Strong 2016 Operating Results 292
6.53 Oct 11, 2016: Inivata Launches US Clinical Trial of Innovative ctDNA Liquid Biopsy Analysis in Lung Cancer 294
6.54 Oct 10, 2016: Illumina Announces Preliminary Revenue for Third Quarter of Fiscal Year 2016 294
6.55 Oct 05, 2016: VeriStrat Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy 295
6.56 Oct 04, 2016: IncellDxs Quantitative Immuno-Oncology Assay OncoTect iO Published in New Study 295
6.57 Sep 29, 2016: Intuitive Surgical to Form Joint Venture with Shanghai Fosun Pharma 296
6.58 Sep 29, 2016: VolitionRX Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 296
6.59 Sep 29, 2016: GlaxoSmithKline appoints Brian McNamara as CEO of GSK Consumer Healthcare 296
6.60 Sep 28, 2016: Quanterix Invests in Immunarray 297
6.61 Sep 28, 2016: Change To Astrazeneca Board Of Directors 297
6.62 Sep 26, 2016: Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation 297
6.63 Sep 26, 2016: Rosetta Genomics Reports 2016 Second Quarter Financial Results 298
6.64 Sep 22, 2016: Owlstone Medical commences next phase in worlds largest breath-based clinical trial for early cancer detection 300
6.65 Sep 22, 2016: MDxHealth Announces Upgraded Revenue Forecast 301
6.66 Sep 20, 2016: New Data Highlights Effectiveness of EarlyCDT-Lung in Assessing Lung Cancer Risk of Nodules Detected During CT Screening 302
6.67 Sep 20, 2016: Emma Walmsley to succeed Andrew Witty as Chief Executive Officer of GlaxoSmithKline 302
6.68 Sep 20, 2016: LabCorp Names Veteran Biopharma Executive John Ratliff CEO of Covance Drug Development 303
6.69 Sep 19, 2016: BioMarker Strategies Awarded Phase I National Cancer Institute Contract to Develop Novel Predictive Test for Response to Immunotherapies for Patients with Non-Small Cell Lung Cancer 304
6.70 Sep 15, 2016: Agilent Technologies Raises USD300 Million in Public Offering of Notes Due 2026 304
6.71 Sep 15, 2016: Proteome Sciences: Interim Results 304
6.72 Sep 13, 2016: Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028 305
6.73 Sep 13, 2016: Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023 305
6.74 Sep 13, 2016: OPKO Health Appoints Jane Pine Wood as Chief Legal and Compliance Officer of BioReference Laboratories 305
6.75 Sep 13, 2016: Online Disruptive Technologies Announces Asian Patents and Initial Test Results 305
6.76 Sep 12, 2016: Dynacare offers the PD-L1 Companion Diagnostic for Keytruda, for the treatment of lung cancer 306
6.77 Sep 09, 2016: Case for Liquid Biopsies Builds in Advanced Lung Cancer 307
6.78 Sep 07, 2016: Armune BioScience Raises USD5 Million in Series A Venture Financing 309
6.79 Sep 07, 2016: Pfizer Appoints Chief Scientific Officer for Neuroscience Research 309
6.80 Sep 05, 2016: Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials 309
6.81 Sep 02, 2016: Danaher Acquires Cepheid 313
7 Appendix 461
7.1 Methodology 461
7.2 About GlobalData 464
7.3 Contact Us 464
7.4 Disclaimer 464

List of Tables
Table 1: Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 28
Table 2: Lung Cancer Diagnostic Tests - Pipeline Products by Territory 29
Table 3: Lung Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 30
Table 4: Lung Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 31
Table 5: Lung Cancer Diagnostic Tests - Ongoing Clinical Trials 32
Table 6: Lung Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 33
Table 7: Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 38
Table 8: A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 43
Table 9: Onco 88 - Lung Cancer - Product Status 43
Table 10: Onco 88 - Lung Cancer - Product Description 44
Table 11: OncoStain 88 - Lung Cancer - Product Status 44
Table 12: OncoStain 88 - Lung Cancer - Product Description 44
Table 13: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 45
Table 14: ACTN4 Companion Diagnostic Assay - Lung Cancer - Product Status 45
Table 15: ACTN4 Companion Diagnostic Assay - Lung Cancer - Product Description 46
Table 16: ALK Companion Diagnostic Assay - Lung Cancer - Product Status 46
Table 17: ALK Companion Diagnostic Assay - Lung Cancer - Product Description 46
Table 18: ARCHITECT ci8200 Integrated System - NSE Assay - Product Status 47
Table 19: ARCHITECT ci8200 Integrated System - NSE Assay - Product Description 47
Table 20: cMET Companion Diagnostic Assay - Lung Cancer - Product Status 47
Table 21: cMET Companion Diagnostic Assay - Lung Cancer - Product Description 48
Table 22: EML4 Companion Diagnostic Assay - Lung Cancer - Product Status 48
Table 23: EML4 Companion Diagnostic Assay - Lung Cancer - Product Description 48
Table 24: Heregulin Companion Diagnostic Assay - Lung Cancer - Product Status 49
Table 25: Heregulin Companion Diagnostic Assay - Lung Cancer - Product Description 49
Table 26: MAGE-A3 Companion Lung Cancer Assay - Product Status 49
Table 27: MAGE-A3 Companion Lung Cancer Assay - Product Description 50
Table 28: PIK3CA Companion Diagnostic Assay - Lung Cancer - Product Status 50
Table 29: PIK3CA Companion Diagnostic Assay - Lung Cancer - Product Description 50
Table 30: PRAME Antigen Lung Cancer Assay - Product Status 51
Table 31: PRAME Antigen Lung Cancer Assay - Product Description 51
Table 32: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 52
Table 33: Diagnostic Assay - Lung Cancer - Product Status 52
Table 34: Diagnostic Assay - Lung Cancer - Product Description 52
Table 35: MCM Test - Lung Cancer - Product Status 53
Table 36: MCM Test - Lung Cancer - Product Description 53
Table 37: Aberystwyth University Pipeline Products & Ongoing Clinical Trials Overview 54
Table 38: Diagnostic Biomarker Test - Lung Cancer - Product Status 54
Table 39: Diagnostic Biomarker Test - Lung Cancer - Product Description 54
Table 40: Acobiom Pipeline Products & Ongoing Clinical Trials Overview 55
Table 41: Companion Diagnostic Test - Lung Cancer - Product Status 55
Table 42: Companion Diagnostic Test - Lung Cancer - Product Description 55
Table 43: Advanced Marker Discovery SL Pipeline Products & Ongoing Clinical Trials Overview 56
Table 44: Predictive Diagnostic Test - Lung Cancer - Product Status 56
Table 45: Predictive Diagnostic Test - Lung Cancer - Product Description 56
Table 46: Prognostic Test - Lung Cancer - Product Status 57
Table 47: Prognostic Test - Lung Cancer - Product Description 57
Table 48: Advpharma Inc Pipeline Products & Ongoing Clinical Trials Overview 58
Table 49: Lung Cancer Prognostic Assay - Product Status 58
Table 50: Lung Cancer Prognostic Assay - Product Description 58
Table 51: Molecular Diagnostic Biomarker - Lung Cancer - Product Status 59
Table 52: Molecular Diagnostic Biomarker - Lung Cancer - Product Description 59
Table 53: AIT Austrian Institute of Technology GmbH Pipeline Products & Ongoing Clinical Trials Overview 60
Table 54: Biomarker Assay - Lung Cancer - Product Status 60
Table 55: Biomarker Assay - Lung Cancer - Product Description 60
Table 56: Almac Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 61
Table 57: Prognostic Test - Early Stage Lung Cancer - Product Status 61
Table 58: Prognostic Test - Early Stage Lung Cancer - Product Description 61
Table 59: Prognostic Test - NSCLC - Product Status 62
Table 60: Prognostic Test - NSCLC - Product Description 62
Table 61: Armune BioScience, Inc. Pipeline Products & Ongoing Clinical Trials Overview 63
Table 62: Diagnostic Test - Lung Cancer - Product Status 63
Table 63: Diagnostic Test - Lung Cancer - Product Description 63
Table 64: Aurelium BioPharma Inc. Pipeline Products & Ongoing Clinical Trials Overview 64
Table 65: Lung Cancer Screening Test - Product Status 64
Table 66: Lung Cancer Screening Test - Product Description 64
Table 67: Avant Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 65
Table 68: TheraLink Assay - Non-Small Cell Lung Cancer - Product Status 65
Table 69: TheraLink Assay - Non-Small Cell Lung Cancer - Product Description 65
Table 70: BioAffinity Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 66
Table 71: CyPath Lung - Product Status 66
Table 72: CyPath Lung - Product Description 66
Table 73: Biocept Inc Pipeline Products & Ongoing Clinical Trials Overview 67
Table 74: MicroRNA Test - Lung Cancer - Product Status 67
Table 75: MicroRNA Test - Lung Cancer - Product Description 68
Table 76: BioChain Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 69
Table 77: Blood - Based Lung Cancer Test - Product Status 69
Table 78: Blood - Based Lung Cancer Test - Product Description 69
Table 79: BioChain Institute Inc - Ongoing Clinical Trials Overview 70
Table 80: Blood - Based Lung Cancer Test - BioChain Clinical Trial on novel, blood-based lung cancer test 70
Table 81: Biodesix Inc Pipeline Products & Ongoing Clinical Trials Overview 71
Table 82: TAm-Seq NGS Lung Cancer Test - Product Status 71
Table 83: TAm-Seq NGS Lung Cancer Test - Product Description 71
Table 84: BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 72
Table 85: Metabolomics-based Diagnostic Assay - Lung Cancer - Product Status 72
Table 86: Metabolomics-based Diagnostic Assay - Lung Cancer - Product Description 72
Table 87: BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview 73
Table 88: Ex Vivo Biomarker Test - Lung Cancer - Product Status 73
Table 89: Ex Vivo Biomarker Test - Lung Cancer - Product Description 73
Table 90: PathMAP NSCLC - Product Status 74
Table 91: PathMAP NSCLC - Product Description 74
Table 92: BioNTech AG Pipeline Products & Ongoing Clinical Trials Overview 75
Table 93: Lung Cancer Screening Test - Product Status 75
Table 94: Lung Cancer Screening Test - Product Description 75
Table 95: BioSystems International Pipeline Products & Ongoing Clinical Trials Overview 76
Table 96: QuantiPlasma Antibody Based Test - Lung Cancer - Product Status 76
Table 97: QuantiPlasma Antibody Based Test - Lung Cancer - Product Description 76
Table 98: BioTime Inc Pipeline Products & Ongoing Clinical Trials Overview 77
Table 99: PanC-Dx - Lung Cancer - Product Status 77
Table 100: PanC-Dx - Lung Cancer - Product Description 78
Table 101: Cangen Biotechnologies Inc Pipeline Products & Ongoing Clinical Trials Overview 79
Table 102: Diagnostic Test - Early Stage Lung Cancer - Product Status 79
Table 103: Diagnostic Test - Early Stage Lung Cancer - Product Description 79
Table 104: Cellanyx Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 80
Table 105: Cellanyx Test - Lung Cancer - Product Status 80
Table 106: Cellanyx Test - Lung Cancer - Product Description 80
Table 107: CellMax Life Pipeline Products & Ongoing Clinical Trials Overview 81
Table 108: Diagnostic Assay - Lung Cancer - Product Status 81
Table 109: Diagnostic Assay - Lung Cancer - Product Description 81
Table 110: CeMines, Inc. Pipeline Products & Ongoing Clinical Trials Overview 82
Table 111: CellCorrect LAb Test For Lung Cancer - Product Status 82
Table 112: CellCorrect LAb Test For Lung Cancer - Product Description 82
Table 113: Cepheid Pipeline Products & Ongoing Clinical Trials Overview 83
Table 114: Xpert Lung CA Early Detection Test - Product Status 83
Table 115: Xpert Lung CA Early Detection Test - Product Description 84
Table 116: Xpert OncoScreen Lung Cancer Assay - Product Status 84
Table 117: Xpert OncoScreen Lung Cancer Assay - Product Description 84
Table 118: Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 85
Table 119: Nanotrap Lung Cancer Biomarker Test - Product Status 85
Table 120: Nanotrap Lung Cancer Biomarker Test - Product Description 85
Table 121: Cernostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 86
Table 122: TissueCypher Lung Cancer Test - Product Status 86
Table 123: TissueCypher Lung Cancer Test - Product Description 86
Table 124: ChemImage Corporation Pipeline Products & Ongoing Clinical Trials Overview 87
Table 125: Prognostic Test - Lung Cancer - Product Status 87
Table 126: Prognostic Test - Lung Cancer - Product Description 87
Table 127: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 88
Table 128: Collagen XXIII Biomarker Assay - NSCLC - Product Status 88
Table 129: Collagen XXIII Biomarker Assay - NSCLC - Product Description 88
Table 130: Clarient Inc Pipeline Products & Ongoing Clinical Trials Overview 89
Table 131: ALK PCR Test - NSCLC - Product Status 89
Table 132: ALK PCR Test - NSCLC - Product Description 89
Table 133: PulmoTax - Product Status 90
Table 134: PulmoTax - Product Description 90
Table 135: Courtagen Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 91
Table 136: Lung Cancer Diagnostic Panel - Product Status 91
Table 137: Lung Cancer Diagnostic Panel - Product Description 91
Table 138: DiagnoCure Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 92
Table 139: Diagnostic Test - Lung Cancer - Product Status 92
Table 140: Diagnostic Test - Lung Cancer - Product Description 93
Table 141: EDP Biotech Corporation Pipeline Products & Ongoing Clinical Trials Overview 94
Table 142: PulmoMarker Test - Product Status 94
Table 143: PulmoMarker Test - Product Description 94
Table 144: Emory University Pipeline Products & Ongoing Clinical Trials Overview 95
Table 145: Biomarker Assay - Small Cell Lung Cancer - Product Status 95
Table 146: Biomarker Assay - Small Cell Lung Cancer - Product Description 95
Table 147: Epigenomics AG Pipeline Products & Ongoing Clinical Trials Overview 96
Table 148: Epi proLung BL 1.0 - Blood Plasma - Product Status 96
Table 149: Epi proLung BL 1.0 - Blood Plasma - Product Description 97
Table 150: Screening And Monitoring Test - Lung Cancer - Product Status 97
Table 151: Screening And Monitoring Test - Lung Cancer - Product Description 97
Table 152: Eventus Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 98
Table 153: Octava Test - Lung Cancer - Product Status 98
Table 154: Octava Test - Lung Cancer - Product Description 98
Table 155: Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 99
Table 156: Blood-based Lung Cancer Screening Test - Product Status 99
Table 157: Blood-based Lung Cancer Screening Test - Product Description 100
Table 158: Exiqon A/S Pipeline Products & Ongoing Clinical Trials Overview 101
Table 159: miRNA Test - Lung Cancer - Product Status 101
Table 160: miRNA Test - Lung Cancer - Product Description 101
Table 161: Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview 102
Table 162: EXOTEST Lung - Product Status 102
Table 163: EXOTEST Lung - Product Description 102
Table 164: Fahy Gurteen UK Ltd Pipeline Products & Ongoing Clinical Trials Overview 103
Table 165: Diagnostic Test - Lung Cancer - Product Status 103
Table 166: Diagnostic Test - Lung Cancer - Product Description 103
Table 167: Fina Biotech Pipeline Products & Ongoing Clinical Trials Overview 104

1.2 List of Figures
Figure 1: Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 28
Figure 2: Lung Cancer Diagnostic Tests - Pipeline Products by Territory 29
Figure 3: Lung Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 30
Figure 4: Lung Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 31
Figure 5: Lung Cancer Diagnostic Tests - Ongoing Clinical Trials 32

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *